-
1Academic Journal
Authors: A. Y. Belyaev, N. B. Vikhrova, D. B. Kalaeva, A. I. Batalov, R. M. Afandiev, S. A. Galstyan, G. L. Kobyakov, I. N. Pronin, D. Y. Usachev, А. Ю. Беляев, Н. Б. Вихрова, Д. Б. Калаева, А. И. Баталов, Р. М. Афандиев, С. А. Галстян, Г. Л. Кобяков, И. Н. Пронин, Д. Ю. Усачев
Contributors: Исследование выполнено при финансовой поддержке Минобрнауки в рамках научного проекта № 075-15-2020-809.
Source: Medical Visualization; Том 26, № 4 (2022); 82-92 ; Медицинская визуализация; Том 26, № 4 (2022); 82-92 ; 2408-9516 ; 1607-0763
Subject Terms: метаболический объем опухоли, 11 C-methionine, anaplastic astrocytomas, anaplastic oligodendrogliomas, IDH, metabolic tumor volume, 11 С-метионин, анапластическая астроцитома, анапластическая олигодендроглиома
File Description: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/1269/761; McNeill K.A. Epidemiology of Brain Tumors. Neurologic. Clinics. 2016; 34 (4): 981–998. https://doi.org/10.1016/j.ncl.2016.06.014; Ostrom Q.T., Patil N., Cioffi G. et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncology. 2020; 22 (Suppl. 1): iv1–iv96. https://doi.org/10.1093/neuonc/noaa200; Suzuki, H., Aoki, K., Chiba, K. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2015; 47 (3): 458–468. https://doi.org/10.1007/s00401-015-1398-z; Katsanos A.H., Alexiou G.A., Fotopoulos A.D. et al. Performance of 18 F-FDG, 11 C-Methionine, and 18 F-FET PET for Glioma Grading. Clin. Nuclear Med. 2019; 44 (11): 864–869. https://doi.org/10.1097/RLU.0000000000002654; Takei H., Shinoda J., Ikuta S. et al. Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system. J. Neurosurg. 2020; 133 (4): https://doi.org/10.3171/2019.5.JNS19780; Law I., Albert N.L., Arbizu J. et al. Joint EANM/EANO/ RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18 F]FDG: version 1.0. Eur. J. Nucl. Med. Mol. Imaging. 2019; 46 (3): 540–557. https://doi.org/10.1007/s00259-018-4207-9; Weller M., van den Bent M., Tonn J.C. et al.; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017; 18 (6): e315–e329. https://doi.org/10.1016/S1470-2045(17)30194-8; Shinozaki N., Uchino Y., Yoshikawa K. et al. Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11 C-methionine positron emission tomography. J. Neurosurg. 2011; 114 (6): 1640–1647. https://doi.org/10.3171/2010.11.JNS10553; Hatakeyama T., Kawai N., Nishiyama Y. et al. 11 C-methionine (MET) and18 F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur. J. Nucl. Med. Mol. Imaging. 2008; 35 (11): 2009–2017. https://doi.org/10.1007/s00259-008-0847-5; Kato T., Shinoda J., Nakayama N. et al. Metabolic Assessment of Gliomas Using 11 C-Methionine, [18 F] Fluorodeoxyglucose, and 11 C-Choline Positron-Emission Tomography. Am. J. Neuroradiol. 2008; 29 (6): 1176–1182. https://doi.org/10.3174/ajnr.A1008; Song S., Cheng Y., Ma J. et al. Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. Eur. J. Nucl. Med. Mol. Imaging. 2020; 47 (6): 1458–1467. https://doi.org/10.1007/s00259-019-04656-2; Unterrainer M., Fleischmann D.F., Vettermann F. et al. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative18 F-GE-180 PET study. Eur. J. Nucl. Med. Mol. Imaging. 2020; 47 (6): 1368–1380. https://doi.org/10.1007/s00259-019-04491-5; Okita Y., Shofuda T., Kanematsu D. et al. The association between 11 C-methionine uptake, IDH gene mutation, and MGMT promoter methylation in patients with grade II and III gliomas. Clin. Radiol. 2020; 75 (8), 622–628. https://doi.org/10.1016/j.crad.2020.03.033; Kim D., Chun J.-H., Kim S.H. et al. Re-evaluation of the diagnostic performance of 11 C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas. Eur. J. Nucl. Med. Mol. Imaging. 2019; 46 (8): 1678–1684. https://doi.org/10.1007/s00259-019-04337-0; Verger A., Metellus P., Sala Q. et al. IDH mutation is paradoxically associated with higher 18 F-FDOPA PET uptake in diffuse grade II and grade III gliomas. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (8): 1306–1311. https://doi.org/10.1007/s00259-017-3668-6; Ogawa T., Kawai N., Miyake K. et al. Diagnostic value of PET/CT with 11 C-methionine (MET) and 18 F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification. EJNMMI Research. 2020; 10 (1): 44. https://doi.org/10.1186/s13550-020-00633-1; Kebir S., Lazaridis L., Weber M. et al. Comparison of l-Methyl- 11 C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma. Clin. Nucl. Med. 2019; 44 (6): e375–e381. https://doi.org/10.1097/RLU.0000000000002577; Saito T., Maruyama T., Muragaki Y. et al. 11 C-Methionine Uptake Correlates with Combined 1p and 19q Loss of Heterozygosity in Oligodendroglial Tumors. Am. J. Neuroradiol. 2013; 34 (1): 85–91. https://doi.org/10.3174/ajnr.A3173; Verger A., Stoffels G., Bauer E.K. et al. Static and dynamic18 F–FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur. J. Nucl. Med. Mol. Imaging. 2018; 45 (3): 443–451. https://doi.org/10.1007/s00259-017-3846-6; Nakajo K., Uda T., Kawashima T. et al. Diagnostic Performance of [11 C]Methionine Positron Emission Tomography in Newly Diagnosed and Untreated Glioma Based on the Revised World Health Organization 2016 Classification. Wld Neurosurg. 2021; 148: e471–e481. https://doi.org/10.1016/j.wneu.2021.01.012; https://medvis.vidar.ru/jour/article/view/1269
-
2Academic Journal
Authors: Насхлеташвили, Д., Бекяшев, А., Карахан, В., Алешин, В., Фу, Р., Белов, Д., Чмутин, Е.
Subject Terms: АНАПЛАСТИЧЕСКАЯ ОЛИГОДЕНДРОГЛИОМА, ХИМИОТЕРАПИЯ, ПРОКАРБАЗИН
File Description: text/html
-
3Academic Journal
Authors: Штефан, А. Ю., Сакаева, Д. Д., Муфазалов, Ф. Ф.
Subject Terms: ЗЛОКАЧЕСТВЕННЫЕ ГЛИОМЫ, ЛУЧЕВАЯ ТЕРАПИЯ, ХИМИОЛУЧЕВОЕ ЛЕЧЕНИЕ, АНАПЛАСТИЧЕСКАЯ ОЛИГОДЕНДРОГЛИОМА, АНАПЛАСТИЧЕСКАЯ ОЛИГОАСТРОЦИТОМА АНАПЛАСТИЧЕСКАЯ АСТРОЦИТОМА, ГЛИОБЛАСТОМА
File Description: application/pdf
Relation: Уральский медицинский журнал. 2007. Т. 30, № 2.; http://elib.usma.ru/handle/usma/17312
Availability: http://elib.usma.ru/handle/usma/17312
-
4Academic Journal
Authors: Штефан, А., Сакаева, Д., Муфазалов, Ф.
Subject Terms: ЗЛОКАЧЕСТВЕННЫЕ ГЛИОМЫ, ЛУЧЕВАЯ ТЕРАПИЯ, ХИМИОЛУЧЕВОЕ ЛЕЧЕНИЕ, АНАПЛАСТИЧЕСКАЯ ОЛИГОДЕНДРОГЛИОМА, АНАПЛАСТИЧЕСКАЯ ОЛИГОАСТРОЦИТОМА АНАПЛАСТИЧЕСКАЯ АСТРОЦИТОМА, ГЛИОБЛАСТОМА
File Description: text/html
-
5Academic Journal
Source: Опухоли головы и шеи.
File Description: text/html
-
6Academic Journal
Source: Медицинский вестник Башкортостана.
Subject Terms: ЗЛОКАЧЕСТВЕННЫЕ ГЛИОМЫ, ЛУЧЕВАЯ ТЕРАПИЯ, ХИМИОЛУЧЕВОЕ ЛЕЧЕНИЕ, АНАПЛАСТИЧЕСКАЯ ОЛИГОДЕНДРОГЛИОМА, АНАПЛАСТИЧЕСКАЯ ОЛИГОАСТРОЦИТОМА АНАПЛАСТИЧЕСКАЯ АСТРОЦИТОМА, ГЛИОБЛАСТОМА, 3. Good health
File Description: text/html
